Published May 5, 2026 | Version v1

Co-Processed Excipients in Sustained Release Tablet: A Quality by Design-Based Review

Description

Sustained release (SR) tablets are designed to release therapeutic agents at a predetermined rate, improving patient compliance, reducing dosing frequency, and maintaining consistent plasma drug levels. Traditional excipients often face limitations such as poor compressibility, flow, and stability, which can compromise the performance of SR formulations. Co-processed excipients, developed by combining two or more excipients through specialized processing techniques such as spray drying, melt granulation, co-precipitation, and solvent evaporation, offer enhanced mechanical, flow, and functional properties. Integrating the Quality by Design (QbD) approach in the development of SR tablets enables a systematic, science- and risk-based framework that ensures product quality is built into the formulation. Core elements of QbD, including Quality Target Product Profile (QTPP), Critical Quality Attributes (CQA), Critical Material Attributes (CMA), and Critical Process Parameters (CPP), coupled with tools such as risk assessment, Design of Experiments (DoE), and statistical modeling, allow precise optimization of co-processed excipient-based formulations. The application of QbD facilitates reduced batch failures, improved regulatory flexibility, and development of robust and reproducible tablets. Future trends such as artificial intelligence-driven formulation optimization, advanced co-processing techniques, and continuous manufacturing are expected to further enhance SR tablet development. Overall, the combination of co-processed excipients and QbD represents a strategic pathway for producing high-quality, patient-centric sustained release formulations

Files

22-Darshana Deshmukh.pdf

Files (4.5 MB)

Name Size
md5:36e406d5af5ee077607f7baa0bb4201d
4.5 MB Preview Download